Corporations, democracy, and the public good

Journal of Management Inquiry

Volumn 16, Issue 3, 2007, Pages 201-215

  Barley, Stephen R ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

Lobbying; Private military firms; Privatization

Indexed keywords

EID: 34548734361     PISSN: 10564926     EISSN: 15526542     Source Type: Journal    
DOI: 10.1177/1056492607305891     Document Type: Article

References (34)

1. Amnesty International. (2006). Annual report: Outsourcing facilitating human rights violations. Retrieved August 2006 from http://www.amnestyusa.org/ annualreport/2006/overview.html
2. Bakan, J. (2004). The corporation: The pathological pursuit of profit and power. New York: Free Press.
3. Bierce, A. (1999). The devil's dictionary. New York: Oxford University Press. (Original work published 1911 )
4. Dreyfuss, R. (1997). Popping contributions: The new battle for the FDA. The American Prospect, pp. 53-59.
5. Hartmann, T. (2002). Unequal protection: The rise of corporate dominance and the theft of human rights. New York: Rodale.
6. Hickson, D.J., Hinings, C.R., Lee, C.A., Schneck, R.E., & Pennings, J.M. (1971). A strategic contingencies' theory of interorganizational power. Administrative Science Quarterly, 16, 216-229.
7. Himmelstein, D.U., Warren, E., Thorne, D., & Woolhandler, S. (2005). Illness and injury as contributors to bankruptcy. Health Affairs, 24, 63-73.
8. Hinings, C.R., Hickson, D.J., Pennings, J.M., & Schneck, R.E. (1974). Structural conditions of intraorganizational power. Administrative Science Quarterly, 19, 22-44.
9. Jacoby, M.B., Sullivan, T.A., & Warren, E. (2001). Rethinking the debates over health care financing: Evidence from the bankruptcy courts. New York University Law Review, 76 (2). 375-218.
10. Jensen, S. (2005). A legislative history of the Bankruptcy Abuse Prevention and Consumer Protection Act of 2005. American Bankruptcy Law Journal, 79, 485-569.
11. Kuhlik, B.N. (1992). Industry funding of improvements in the FDA's new drug approval process: The Prescription Drug User Fee Act of 1992. Food and Drug Law Journal, 47, 483-503.
12. Markey, E.J. (2005). Conspiracy of silence: How the FDA allows drug companies to abuse the accelerated approval process. Washington, DC: Congressional Printing Office.
13. Nace, T. (2003). Gangs of America: The rise of corporate power and the disabling of democracy. San Francisco: Berrett-Koehler.
14. Olson, M.K. (2000). Regulatory reform and bureaucratic responsiveness to firms: The impact of user fees in the FDA. Journal of Economics and Management Strategy, 9, 363-395.
15. Olson, M.K. (2002 a). How have user fees affected the FDA? Regulation, 25, 20-25.
16. Olson, M.K. (2002 b). Pharmaceutical policy change and the safety of new drugs. Journal of Law and Economics, 45, 615-642.
17. Olson, M.K. (2004 a). Are novel drugs more risky for patients than less novel drugs? Journal of Health Economics, 23, 1154-1158.
18. Olson, M.K. (2004 b). Managing delegation in the FDA: Reducing delay in new-drug review. Journal of Health Politics, Policy and Law, 29, 397-430.
19. Perrow, C. (2002). Organizing America: Wealth, power and the origins of corporate capitalism. Princeton, NJ: Princeton University Press.
20. Pfeffer, J., & Salancik, G.R. (1978). The external control of organizations: A resource dependence perspective. New York: Harper & Row.
21. Prechel, H. (2000). Big business and the state: Historical transitions and corporate transformation, 1880s-1990s. Albany: SUNY Press.
22. Santa Clara County v. Southern Pacific Railroad Co., 118 U.S. 394 (1886).
23. Simpson, J., & Weiner, E. (Eds.). (1989). Oxford English dictionary (2 nd ed.). Oxford, UK: Clarendon.
24. Singer, P.W. (2003). Corporate warriors: The rise of the privatized military industry. Ithaca, NY: Cornell University Press.
25. Singer, P.W. (2004). Warriors for hire in Iraq. Retrieved August 3, 2006, from http://dir.salon.com/story/news/feature/2004/04/15/warriors/index.html
26. Stern, R.N., & Barley, S.R. (1996). Organizations and social systems: Organization theory's neglected mandate. Administrative Science Quarterly, 41, 146-162.
27. Sullivan, T.A., Warren, E., & Westbrook, J. (2001). The fragile middle class: Americans in debt. New Haven, CT: Yale University Press.
28. Timmerman, L. (2002). FDA to boost its user fees: Drug industry cash will add regulatory staffing The Seattle Times, p. 2.
29. U.S. Food and Drug Administration. (2005 a). FDA history. Retrieved August 2005 from http://www.fda.gov/oc/history/default.htm
30. U.S. Food and Drug Administration. (2005 b). Mission. Retrieved August 2005 from http://www.fda.gov/opacom/morechoices/mission.html
31. U.S. General Accounting Office. (2002). Food and Drug Administration: Effect of user fees on drug approval times, withdrawals and other agency activities. Washington, DC: Government Printing Office.
32. Warren, E. (1998). The bankruptcy crisis. Indiana Law Journal, 73, 1079-1094.
33. Willman, D. (2000). FDA drug approvals reexamined. Contra Costa Times, p. 10.
34. Woolley, J., & Peters, G. (2005). The American presidency project, Andrew Jackson, fifth annual message. Retrieved August 2005 from http://www.presidency.ucsb.edu/ws/index.php?pid=29475